ERBB2 and breast adenocarcinoma: Previously, using HER2+ breast adenocarcinoma cell line SK-BR-3, we observed a noteworthy reduction in the inhibitory effects of the EGFR/HER2-targeting drug lapatinib on cell growth when human blood serum was present in the growth media (Shaban et al., 2024).